TCBP(Delisted)
TC BioPharm·NASDAQ
--
--(--)
TCBP fundamentals
During Q2 2024, TC BioPharm (TCBP) reported revenue of --, a YoY change of 0.00%. Net income was -2.51M, a YoY change of -298.99%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2020 | Q4,2020 | Q3,2021 | Q4,2021 | Q1,2023 | Q2,2023 | Q1,2024 | Q2,2024 | TTM |
|---|
Start Date | Jul 1, 2020 | Oct 1, 2020 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2023 | Apr 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | -- |
End Date | Sep 30, 2020 | Dec 31, 2020 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2023 | Jun 30, 2023 | Mar 31, 2024 | Jun 30, 2024 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 639.16K -- | 675.81K -- | 666.31K +4.25% | 667.80K -1.19% | -- -- | -- -- | -- -- | -- -- | -- -- |
Sales and Services Revenue | 639.16K -- | 675.81K -- | 666.31K +4.25% | 667.80K -1.19% | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | 0 -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gross Profit | 639.16K -- | 675.81K -- | 666.31K +4.25% | 667.80K -1.19% | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 2.41M -- | 2.88M -- | 3.70M +53.79% | 3.78M +31.24% | 5.15M -- | 4.57M -- | 4.35M -15.59% | 2.60M -43.19% | -- -- |
Selling, General and Administrative Expenses | 614.87K -- | 759.00K -- | 1.41M +129.39% | 1.59M +109.25% | 2.76M -- | 1.90M -- | 2.71M -1.90% | 1.41M -25.75% | -- -- |
Research and Development Expenses | 1.99M -- | 2.14M -- | 2.16M +8.38% | 2.22M +3.75% | 2.39M -- | 2.67M -- | 1.64M -31.39% | 1.19M -55.58% | -- -- |
Other Operating Expenses | -201.05K -- | -18.73K -- | 130.84K +165.08% | -28.02K -49.57% | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Income | -1.77M -- | -2.21M -- | -3.03M -71.70% | -3.11M -41.17% | -5.15M -- | -4.57M -- | -4.35M +15.59% | -2.60M +43.19% | -- -- |
Non-Operating Income (Loss) | -95.10K -- | -94.01K -- | -6.80M -7052.10% | -2.99M -3078.69% | 3.87M -- | 5.45M -- | 11.45K -99.70% | -47.51K -100.87% | -- -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -5.25M -- | -393.75K -- | 3.87M -- | 5.45M -- | 11.45K -99.70% | -47.51K -100.87% | -- -- |
Net Interest Expense | 95.10K -- | 94.01K -- | 1.55M +1534.10% | 2.59M +2659.85% | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Expense | 95.14K -- | 94.57K -- | 1.55M +1533.40% | 2.59M +2643.51% | -- -- | -- -- | -- -- | -- -- | -- -- |
Interest Income | 41.35 -- | 560.14 -- | 9.43 -77.19% | 6.75 -98.79% | -- -- | -- -- | -- -- | -- -- | -- -- |
Pretax Income From Continuing Operations | -1.86M -- | -2.30M -- | -9.84M -428.12% | -6.10M -165.33% | -1.28M -- | 880.59K -- | -4.34M -238.87% | -2.64M -400.33% | -- -- |
Income Tax Expense | -312.21K -- | -495.30K -- | -370.35K -18.62% | -837.12K -69.01% | -494.76K -- | -381.27K -- | -139.94K +71.71% | -133.71K +64.93% | -- -- |
Net Income | -1.55M -- | -1.80M -- | -9.47M -510.58% | -5.27M -191.77% | -785.32K -- | 1.26M -- | -4.20M -434.54% | -2.51M -298.99% | -- -- |
Net Income Attributable to Owners of the Company | -1.55M -- | -1.80M -- | -9.47M -510.58% | -5.27M -191.77% | -785.32K -- | 1.26M -- | -4.20M -434.54% | -2.51M -298.99% | -- -- |
Net Income Attributable to Common Stockholders | -1.55M -- | -1.80M -- | -9.47M -510.58% | -5.27M -191.77% | -785.32K -- | 1.26M -- | -4.20M -434.54% | -2.51M -298.99% | -- -- |
Other Comprehensive Income | 0 -- | 0 -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -1.55M -- | -1.80M -- | -9.47M -510.58% | -5.27M -191.77% | -- -- | 454.95K -- | -- -- | -6.71M -1574.84% | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -1.55M -- | -1.80M -- | -9.47M -510.58% | -5.27M -191.77% | -- -- | 454.95K -- | -- -- | -6.71M -1574.84% | -- -- |
Basic EPS | -- -- | -- -- | -- -- | -0.27 -- | -0.38 -- | 0.51 -- | -0.14 +63.16% | -0.03 -105.88% | -- -- |
Diluted EPS | -- -- | -- -- | -- -- | -- -- | -0.38 -- | -- -- | -0.14 +63.16% | -- -- | -- -- |
You can ask Aime
No Data
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
